The funding comes from the Bill and Melinda Gates Foundation, which previously provided the company with $500,000 for the test's initial development.
The company has developed a proof-of-concept single-pore sensor that it anticipates integrating into a prototype testing platform this year.
FIND said that the consortium will evaluate the impact on clinical trial participants of innovative diagnostic technologies versus current standards of care.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The firm is developing a point-of-need blood test that it anticipates launching as an additional option in the market for active TB screening.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.